Keywords: Talecris, Manufacturing plant expansion, Investment

Talecris to invest $268.7 million to expand Clayton manufacturing plant

Article | 17 November 2009

• Print This

US drugmaker Talecris says it will spend $268.7 million to expand its manufacturing facilities in Clayton, North Carolina, creating 259 new jobs over the next seven years. State and local tax credits and incentive grants will be provided to facilitate the expansion.

Mary Kuhn, executive vice president of operations at Talecris, said:  “Our manufacturing capabilities have grown exponentially in recent years, creating more jobs and local opportunities. We’re excited to continue expanding our business in a region that has been so supportive of the biotechnology industry.”

Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.

Talecris currently employs approximately 4,700 people worldwide and is headquartered in the biotechnology hub of Research Triangle Park, NC. With more than 1,800 full-time workers employed in Johnston County, Talecris is one of the county’s largest employers. The company has hired more than 180 employees this year in Johnston County alone.

The Clayton manufacturing facility produces protein therapies that are used to treat a range of diseases, including immune deficiencies, hemophilia, genetic emphysema, and a rare neurological disorder known as chronic inflammatory demyelinating polyneuropathy (CIDP). The company has 11 approved products on the market, each of them derived from human plasma that is collected primarily from the company’s 71 plasma donation centers nationwide.

To facilitate Talecris’ manufacturing expansion, the state has awarded the company a $250,000 grant from the state’s One North Carolina Fund. In addition, the state Economic Investment Committee today voted to award a Job Development Investment Grant to Talecris.